TSPO

Across TCGA pan-cancer cohorts, TSPO mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated TSPO data layer compared with 23 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher TSPO mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated TSPO expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

CCRCC, LUAD, and COAD are the cancer types where TSPO mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	III,IV	0.315	0.783	.002	64	view →
LUAD	DFS	Median	II,III,IV	0.764	0.929	.004	19	view →
COAD	DFS	Median	All	0.885	1.000	.018	6	view →
PDAC	OS	Tertile	IV	0.231	0.905	.024	6	view →
HNSC	OS	Median	All	1.000	0.484	.038	6	view →
GBM	DFS	Tertile	All	0.649	0.801	.027	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

TSPO–CCRCC (DFS)

Open the CCRCC breakdown →